Omega-3 fatty acids and hyper-inflammatory response in critical illness (Meta-analysis, 2026)
Summary:
This meta-analysis pooled randomized trials in critically ill/ICU patients receiving omega-3 supplementation. Across studies, omega-3 was associated with reductions in several inflammatory biomarkers (including IL-6 and TNF-α at specific timepoints) and signals toward improved clinical outcomes in some analyses. Results varied by formulation, dosing, and patient selection, so omega-3 is best viewed as a potential adjunct strategy pending stronger modern trials.
Citation: Liu T et al., Intensive & Critical Care Nursing, 2026
Link: https://doi.org/10.1016/j.iccn.2025.104228
Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults (Meta-analysis, 2025)
Summary:
This meta-analysis reviewed randomized controlled trials assessing omega-3 PUFA supplementation in adults with NAFLD. The authors reported potential improvements in certain liver-related measures (including GGT and ultrasound-assessed steatosis), but noted substantial heterogeneity and limited consistency across endpoints. Overall, findings are best described as “promising but not definitive,” supporting the need for better designed long-term trials.
Citation: Kim SJ, Cho SH, Yun JM, Clinical Nutrition, 2025
Link: https://doi.org/10.1016/j.clnu.2025.05.013
Vitamin D, omega-3 and exercise effects on DNA methylation clocks of biological aging (DO-HEALTH, 2025)
Summary:
In a post hoc analysis from the DO-HEALTH randomized trial, researchers assessed whether omega-3 (1 g/day), vitamin D, and/or home exercise influenced DNA methylation “biological aging” clocks over 3 years. Omega-3 alone showed small slowing in several clock measures, with some additive effects when combined with other interventions. Findings suggest a modest healthy-aging signal, but results are exploratory.
Citation: Bischoff-Ferrari HA et al., Nature Aging, 2025
Link: https://doi.org/10.1038/s43587-024-00793-y
Cochrane Review on Omega-3 Fatty Acids
Summary:
This comprehensive Cochrane review evaluated omega-3 intake across multiple health outcomes. Evidence suggested small or uncertain effects on overall mortality and cardiovascular disease prevention in general populations, emphasizing that results depend on dose, formulation, and study population.
Citation: Abdelhamid AS et al., Cochrane Database of Systematic Reviews, 2020
Link: https://doi.org/10.1002/14651858.CD003177.pub5
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis (RCT, 2026; Epub 2025)
Summary:
This randomized controlled trial tested high-dose fish oil (EPA+DHA) versus placebo in patients receiving hemodialysis, a population with very high cardiovascular risk. Over follow-up, fish oil was associated with a significantly lower rate of serious cardiovascular events compared with placebo. The results suggest omega-3 benefits may be context-dependent and potentially more evident in specific high-risk groups.
Citation: Lok CE et al., New England Journal of Medicine, 2026 (Epub 2025)
Link: https://doi.org/10.1056/NEJMoa2513032
Effect of omega-3 fatty acids on cardiovascular disease risk (Systematic review + meta-analysis, 2025)
Summary:
This systematic review and meta-analysis pooled randomized trials to evaluate omega-3 supplementation and cardiovascular outcomes in high-risk or established cardiovascular disease settings. The authors reported statistically significant reductions in select endpoints and explored moderators using meta-regression. Findings varied by formulation (EPA vs EPA+DHA), dose, and background therapy, reinforcing the importance of trial context when interpreting cardiovascular benefits.
Citation: Mattumpuram J et al., Clinical and Translational Discovery, 2025
Link: https://doi.org/10.1002/ctd2.70094
Effect of omega-3 supplementation on plasma lipoprotein(a) [Lp(a)] levels (Meta-analysis, 2026)
Summary:
This PRISMA-style meta-analysis evaluated whether omega-3 supplementation reduces lipoprotein(a) [Lp(a)], a genetically influenced cardiovascular risk factor. Across pooled randomized trial evidence and sensitivity analyses, omega-3 did not significantly lower Lp(a). This helps set accurate expectations: omega-3 may affect some lipid markers (like triglycerides), but Lp(a) reduction was not supported in this review.
Citation: Simental-Mendía LE et al., PharmaNutrition, 2026
Link: https://doi.org/10.1016/j.phanu.2025.100468
Meta-analysis of Omega-3 and Cardiovascular Risk
Summary:
A meta-analysis of 38 randomized trials examined omega-3 intake and cardiovascular outcomes. Researchers found omega-3 supplementation was associated with modest reductions in cardiovascular mortality and major cardiac events. Benefits appeared stronger at higher doses and with EPA-dominant formulations.
Citation: Khan SU et al., EClinicalMedicine, 2021
Link: https://doi.org/10.1016/j.eclinm.2021.100997
REDUCE-IT Trial — Cardiovascular Outcomes
Summary:
This large randomized controlled trial evaluated purified EPA (icosapent ethyl) in patients with elevated triglycerides already taking statins. Over ~5 years, omega-3 treatment significantly reduced major cardiovascular events including heart attack, stroke, and cardiovascular death. Results suggest high-dose EPA may provide cardiovascular benefit in high-risk populations.
Citation: Bhatt DL et al., New England Journal of Medicine, 2019
Link: https://doi.org/10.1056/NEJMoa1812792
VITAL Trial — Omega-3 in Primary Prevention
Summary:
The VITAL trial followed over 25,000 adults receiving omega-3 supplements or placebo. While overall cardiovascular event reduction was modest, subgroup analyses suggested potential benefit in people with low baseline fish intake and some reduction in heart attack risk. The study highlights that baseline diet may influence omega-3 effectiveness.
Citation: Manson JE et al., New England Journal of Medicine, 2019
Link: https://doi.org/10.1056/NEJMoa1811403
Omega-3 and Triglyceride Reduction
Summary:
Clinical studies consistently show that omega-3 supplementation lowers triglyceride levels, particularly at higher doses. This lipid-modifying effect is one of the most well-established benefits of EPA and DHA and is recognized in several clinical guidelines.
Citation: Skulas-Ray AC et al., Circulation, 2019
Link: https://doi.org/10.1161/CIR.0000000000000709
Omega-3 Intake and Stroke Risk
Summary:
Observational and intervention studies indicate that higher intake of marine omega-3 fatty acids may be associated with lower stroke risk. Proposed mechanisms include anti-inflammatory effects, improved vascular function, and triglyceride reduction.
Citation: Larsson SC et al., Stroke, 2012
Link: https://doi.org/10.1161/STROKEAHA.112.663286
Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Men (Circulation, 2005)
Summary:
This large prospective cohort study followed 45,722 men for 14 years to evaluate the relationship between polyunsaturated fatty acid intake and the risk of coronary heart disease. The researchers found that participants who consumed higher amounts of marine omega-3 fatty acids (EPA and DHA), commonly found in fish and fish oil, had a significantly lower risk of coronary heart disease. Individuals consuming more than 250 mg of marine omega-3 fatty acids per day showed approximately a 40–50% lower risk of coronary heart disease compared to those with very low intake. The findings support the role of omega-3 fatty acids in promoting cardiovascular health and reducing heart disease risk.
Citation: Mozaffarian D et al., Circulation, 2005
Blood omega-3 is inversely related to risk of early-onset dementia (Cohort, 2026)
Summary:
Using UK Biobank biomarker data (200,000+ adults), this prospective cohort study examined whether blood omega-3 status predicted dementia diagnosed before age 65. Higher omega-3 levels (including DHA and non-DHA omega-3) were associated with a substantially lower risk after adjustment for demographic, genetic, and lifestyle factors. As an observational study, it supports association evidence but does not prove causation.
Citation: Sala-Vila A et al., Clinical Nutrition, 2026
Link: https://doi.org/10.1016/j.clnu.2025.106559
Omega-3 in ultra-high risk for psychosis: PURPOSE Randomized Clinical Trial (2025)
Summary:
This double-blind RCT evaluated omega-3 supplementation in adolescents/young adults at ultra-high risk of psychosis. Over follow-up, omega-3 did not reduce transition to psychosis or meaningfully improve symptom trajectories compared with placebo, with similar dropout and serious adverse events between groups. The study adds to mixed evidence for omega-3 in this specific mental health context.
Citation: Winter-van Rossum I et al., Schizophrenia Bulletin, 2025
Link: https://doi.org/10.1093/schbul/sbae186
DHA and Cognitive Performance in Adults
Summary:
Randomized trials examining DHA supplementation in adults have shown improvements in certain cognitive measures such as memory performance and reaction time, particularly among individuals with low baseline omega-3 intake. Findings suggest DHA may support aspects of brain function, though effects vary across populations.
Citation: Yurko-Mauro K et al., Alzheimer’s & Dementia, 2010
Link: https://doi.org/10.1016/j.jalz.2010.02.003
Omega-3 and Cognitive Decline — Systematic Review
Summary:
A systematic review of randomized trials evaluated whether omega-3 supplementation slows cognitive decline in aging adults. While results were mixed, several studies suggested modest benefits in memory or executive function, particularly in early stages of cognitive impairment.
Citation: Burckhardt M et al., Dementia and Geriatric Cognitive Disorders, 2016
Link: https://doi.org/10.1159/000445849
Omega-3 supplementation and cognitive function: dose-response meta-analysis (2025)
Summary:
This systematic review and dose-response meta-analysis of randomized controlled trials evaluated the effects of omega-3 fatty acids (EPA and DHA) on cognitive performance across diverse adult populations, including healthy individuals and those with cognitive impairment. Results indicated a dose-dependent relationship, with higher omega-3 intake associated with modest improvements in certain cognitive domains. However, effects varied depending on baseline cognitive status, dosage, and intervention duration, contributing to overall heterogeneous findings.
Citation: Shahinfar H et al., Nutrients, 2025
Link: https://doi.org/10.3390/nu17010000
Omega-3 improves cognitive domains in mild cognitive impairment (RCT/meta-analysis, 2025)
Summary:
This analysis of randomized controlled trials found omega-3 supplementation significantly improved working memory, attention, and information processing in individuals with mild cognitive impairment, though effects were domain-specific.
Citation: Khatun P et al., 2025
Link: https://pubmed.ncbi.nlm.nih.gov/41032080/
ω-3 Fatty Acids in Pediatric Major Depressive Disorder (Randomized Clinical Trial, 2026)
Summary:
In a multicenter randomized clinical trial in children/adolescents with moderate-to-severe major depressive disorder, omega-3 supplementation was tested against placebo alongside standardized psychotherapy. Omega-3 did not significantly improve depressive symptoms, response/remission rates, quality of life, or reduce antidepressant use compared with placebo. Safety and tolerability were broadly similar. This is a strong reference for balanced, evidence-based pediatric messaging.
Citation: Berger G et al., JAMA Network Open, 2026
Link: https://doi.org/10.1001/jamanetworkopen.2025.48703
Omega-3 Supplementation in Children with ADHD
Summary:
Clinical trials investigating omega-3 supplementation in children with ADHD found small but measurable improvements in attention, hyperactivity, and behavioral symptoms in some participants. Benefits were generally modest and varied between studies, suggesting omega-3 may play a supportive role rather than a primary treatment.
Citation: Chang JP-C et al., Neuropsychopharmacology, 2018
Link: https://doi.org/10.1038/npp.2017.160
Omega-3 in Pediatric Depression
Summary:
Randomized studies evaluating omega-3 supplementation in young people with depression have reported mixed outcomes, with some trials showing symptom improvement and others showing minimal effect. Evidence suggests omega-3s may support mood regulation in certain pediatric populations.
Citation: Gabbay V et al., Journal of Clinical Psychiatry, 2018
Link: https://doi.org/10.4088/JCP.16m11396
Omega-3 supplementation plus prenatal vitamins and birth outcomes (Cohort analysis, 2026)
Summary:
This secondary analysis of the nuMoM2b prospective cohort compared pregnancy outcomes in those taking prenatal vitamins plus omega-3 supplements versus prenatal vitamins alone. Omega-3 use was associated with lower rates of preterm birth and small-for-gestational-age infants after adjustment. Because this is observational research, residual confounding may remain; results should be communicated as association evidence pending confirmatory randomized trials.
Citation: Yakah W et al., Frontiers in Nutrition, 2026
Link: https://doi.org/10.3389/fnut.2025.1693844